Posted by Michael Wonder on 14 Oct 2019
STA to market sarcoma drug in Australia, New Zealand and SE Asia following license deal
14 October 2019 - Specialised Therapeutics now filing for TGA approval.
Independent pharmaceutical company Specialised Therapeutics Asia has signed a new license deal, enabling it to provide a global advanced sarcoma therapy to patients in Australia, New Zealand and throughout SE Asia.
Yondelis to be made available in Australia via Special Access Program to open November 1.
